Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2020.05.105
Abstract: BACKGROUND Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. OBJECTIVE To provide longer-term efficacy and safety data for bimekizumab from… read more here.
Keywords: week; phase extension; extension study; bimekizumab ... See more keywords
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7889
Abstract: Background Dual neutralisation of IL-17F, in addition to IL-17A, reduces inflammation1 to a greater extent than inhibition of IL-17A alone in disease–relevant cell models. Bimekizumab, a monoclonal antibody that potently and selectively neutralises both IL-17A… read more here.
Keywords: week; pfizer; ucb pharma; bimekizumab ... See more keywords
Bimekizumab for psoriasis.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.6.3400572
Abstract: Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper… read more here.
Keywords: treatment; psoriasis; bimekizumab psoriasis; bimekizumab ... See more keywords